Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00278174 · ClinicalTrials.gov registry record · Phase 2
Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer
A Phase 2 study of Kidney Cancer, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT00278174: Completed Phase 2 study of Kidney Cancer, sponsored by Case Comprehensive Cancer Center.
NCT00278174 is a Phase 2 study of Kidney Cancer that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 7 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00278174, a Phase 2 study of Kidney Cancer, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.
Conditions Studied
Interventions
- BIOLOGICAL recombinant interferon alpha-1b
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-02 |
| Est. Completion | 2007-04 |
| Phase | Phase 2 |
What the finished NCT00278174 record still lists
NCT00278174 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Kidney Cancer appearing as the primary indexed condition, and to 1 intervention - of which recombinant interferon alpha-1b is the first listed.
NCT00278174 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00278174 about?
NCT00278174 is a clinical study titled "Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer". RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.
What is the current status of trial NCT00278174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2005-02. Estimated completion is 2007-04.
What conditions does trial NCT00278174 study?
This clinical trial studies the following conditions: Kidney Cancer.
What interventions are being tested in trial NCT00278174?
The interventions under investigation include: recombinant interferon alpha-1b (BIOLOGICAL).
Who is sponsoring clinical trial NCT00278174?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00278174 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00278174's enrollment target sits among peer trials
7 61st of 60 the lowest of 60 other Kidney Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations
RECRUITING · Phase 2
-
NSAID Use After Robotic Partial Nephrectomy
RECRUITING · Phase 2
-
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
RECRUITING · Phase 2
-
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RECRUITING · Phase 2
-
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
RECRUITING · Phase 2
-
Study of Nivolumab in Combination With 177Lu-girentuximab for Kidney Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia